# Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

> **NCT01040624** · NA · COMPLETED · sponsor: **University of Florida** · enrollment: 77 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** < 15% risk of + LN
- **RADIATION:** > 15% risk of + LN

## Key facts

- **NCT ID:** NCT01040624
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2015-01
- **Final completion:** 2022-04-11
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040624, "Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01040624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*